Table 2 Clinicopathological characteristics of HR+/HER2- vs. triple-negative breast cancers by HER2 IHC scores (n = 1269 vs. 186)

From: HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis

 

HR + 

TNBC

HER2

P-value

HER2

P-value

2+ 

1+ 

L

U

N

2+ vs. 1+ 

U vs. L

U vs. N

N vs. L

2+

1+ 

L

U

N

2+ vs. 1 + 

U vs. L

U vs. N

N vs. L

Age

≤50

182

173

355

41

59

0.378

0.257

0.777

0.352

10

20

30

14

23

0.013

0.155

0.748

0.040

>50

358

303

661

60

93

    

44

29

73

19

27

    

T stage

1–2

528

469

997

98

149

0.377

0.701*

0.685#

1.000*

54

46

100

33

50

0.104#

1.000#

-

0.551#

3–4

12

7

19

3

3

    

0

3

3

0

0

    

N stage

0

355

310

665

67

99

0.825

0.789

0.887

0.601

40

35

75

26

39

0.776

0.344

0.633

0.602

1–3

177

150

327

31

44

    

12

12

24

5

10

    

Histological grade

1

32

33

65

2

7

0.805

0.194

0.141

0.011

0

1

1

0

0

<0.001#

0.162#

0.707#

0.007#

2

428

373

801

83

106

    

23

5

28

4

4

    

3

77

67

144

16

35

    

31

43

74

29

46

    

TILs

<30%

502

442

944

96

140

0.882

0.514

0.360

0.563

43

35

78

22

33

0.425

0.264

0.950

0.172

≥30%

35

32

67

5

12

    

11

13

24

11

17

    

ER

≤10%

16

28

44

3

17

0.023

0.697*

0.018

<0.001

-

-

-

-

-

-

-

 

-

>10%

524

448

972

98

135

             

PR

≤20%

118

93

211

20

41

0.364

0.819

0.192

0.083

-

-

-

-

-

-

-

 

-

>20%

422

383

805

81

111

             

Ki-67

<30%

284

280

564

45

83

0.042

0.034

0.117

0.824

13

4

17

1

0

0.030

0.091*

0.402#

0.003

≥30%

256

195

451

56

69

    

41

45

86

32

50

    
  1. Bold: p values < 0.05. L low, U ultralow, N Null.
  2. P-values with superscript “#” were calculated using continuity correction; P-values with superscript “*” were calculated using Fisher’s exact test.
Back to article page